MAPT and Alzheimer disease: Many aspects of the amyloid and tau pathologies are closely recapitulated in transgenic rodent models for AD (Teipel et al., 2011; Hall and Roberson, 2012), which can be monitored by small animal positron-emission-tomography (μPET) using radioligands targeting the proteins accumulating in AD (Virdee et al., 2012; Zimmer et al., 2014).